These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16315582)

  • 21. Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae.
    Noreddin AM; Hoban DJ; Zhanel GG
    Int J Antimicrob Agents; 2005 Aug; 26(2):120-5. PubMed ID: 16046101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae.
    Ribes S; Taberner F; Domenech A; Cabellos C; Tubau F; Liñares J; Viladrich PF; Gudiol F
    J Antimicrob Chemother; 2006 May; 57(5):931-6. PubMed ID: 16507562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis.
    Ohata Y; Tomita Y; Sunakawa K; Drusano GL; Tanigawara Y
    Int J Antimicrob Agents; 2019 Sep; 54(3):292-300. PubMed ID: 31279154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative activity of cefodizime and ceftriaxone against respiratory pathogens in an in vitro pharmacodynamic model simulating concentration-time curves.
    Blandino G; Milazzo I; Musumeci R; Nicolosi VM; Speciale A; Nicoletti G
    J Chemother; 2000 Dec; 12(6):503-8. PubMed ID: 11154034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S; Erdem H; Pahsa A
    Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial resistance of Streptococcus pneumoniae and Haemophilus influenzae in Sao Paulo, Brazil from 1996 to 2000.
    Koeth LM; Felmingham D; Jacobs MR; Rossi F
    Int J Antimicrob Agents; 2004 Apr; 23(4):356-61. PubMed ID: 15081084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determination of the pharmacodynamic profile of daptomycin against Streptococcus pneumoniae isolates with varying susceptibility to penicillin in a murine thigh infection model.
    Dandekar PK; Tessier PR; Williams P; Zhang C; Nightingale CH; Nicolau DP
    Chemotherapy; 2004 Apr; 50(1):11-6. PubMed ID: 15084799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bactericidal activity of cefepime and ceftriaxone tested against Streptococcus pneumoniae.
    Pottumarthy S; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):345-9. PubMed ID: 17141459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the pharmacokinetics of Aspen Ceftriaxone and Rocephin in community-acquired meningitis.
    Richards GA; Elliott E; Shaddock EJ; Mushi D; Mzileni M; Ray R; Rulisa S; Seolwane F; Stacey SL; Stoltz A; Venturas JP; Schoeman H
    S Afr Med J; 2013 Sep; 103(12):906-9. PubMed ID: 24300626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Susceptibility and bactericidal activity of 8 oral quinolones against conventional-fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Yokota S; Ohkoshi Y; Fujii N
    Diagn Microbiol Infect Dis; 2009 Sep; 65(1):76-80. PubMed ID: 19679241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis.
    Zelenitsky SA; Beahm NP; Iacovides H; Ariano RE; Zhanel G
    J Antimicrob Chemother; 2018 Jul; 73(7):1888-1894. PubMed ID: 29635472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
    Schentag JJ
    J Chemother; 2002 Feb; 14 Suppl 2():13-21. PubMed ID: 12003136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic-pharmacodynamic comparison of ceftriaxone regimens in acute cholangitis.
    Toki M; Yamaguchi Y; Goto T; Yoshida T; Ota H; Ochiai K; Gondo K; Watanabe S; Kurata I; Hisamatsu T
    J Infect Chemother; 2019 Oct; 25(10):780-785. PubMed ID: 31130393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pneumococcal infection in children: rational antibiotic choice for drug-resistant Streptococcus pneumoniae.
    Chiou CC; Hseih KS
    Acta Paediatr Taiwan; 2003; 44(2):67-74. PubMed ID: 12845845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study of pharmacokinetics/pharmacodynamics of levofloxacin].
    Zhang J; Yu JC; Shi YG; Zhou L; Ye XY; Zhu DM; Zhang YY
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1926-32. PubMed ID: 16255991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
    Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
    Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increasing ceftriaxone resistance and multiple alterations of penicillin-binding proteins among penicillin-resistant Streptococcus pneumoniae isolates in Taiwan.
    Chiu CH; Su LH; Huang YC; Lai JC; Chen HL; Wu TL; Lin TY
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3404-6. PubMed ID: 17591850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of pharmacodynamic properties in treatment of penicillin resistant Streptococcus pneumoniae.
    Knudsen JD
    Dan Med Bull; 2000 Nov; 47(5):313-27. PubMed ID: 11155659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.
    Perry TR; Schentag JJ
    Clin Pharmacokinet; 2001; 40(9):685-94. PubMed ID: 11605716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.